3 results
Approved WMOCompleted
To determine the feasibility, toxicity and safety of anti-CEA x anti hapten bispecific antibodies (TF2) and Lu-177-labelled di-HSG-DOTA peptide (IMP-288) in patients with advanced colorectal carcinoma.
Approved WMOCompleted
To investigate the clinical efficacy in detecting clinically relevant arritmia's (especially AF) of the Reveal XT in patients with mild to moderate heart failure and elevated risk factor for stroke and TIA (CHADS score), currelently not treated…
Approved WMOCompleted
To assess the Pharmacokinetic and Pharmacodynamic properties of three dosages of Coagulation Factor VIIa (Recombinant) in congenital hemophilia A or B patientsTo assess the safety of three dosages of Coagulation factor VIIa (Recombinant) in…